Histocompatibility Antigens (HLA-A, B) and Ulcerative Colitis in a Greek Population

Papasteriades, C.; Spiliadis, C.; Emmanouilidis, Anastasios; Papadimitriou, Ch.; Economidou, J.; Manousos, O. N.

doi:10.1159/000199300

Cited by 6 publications

(2 citation statements)

References 6 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apart from the evident immune dysregulation, the three cases described above seem to share a common immunogenetic background through major histocompatibility complex class I (MHC-I), HLA B * alleles (B07, B35, B51, and B55), known for their involvement in the presentation of intracellular and viral components as well as the attempt of cancer cells to evade the anticancer immune response of T cells, through intensified expression of HLA products, also recorded in patients with hematologic malignancies [17]. e B07, a rather frequent allele, already linked to hematological malignancies [18], is also frequently encountered among Greek UC patients and associated with greater disease extent [19]. e presence of B35 has been documented in cases of cosegregated autoimmune disorders, such as UC and Takayasu arteritis, as well as UC and postinfectious Guillain-Barré syndrome (GBS) [20][21][22][23].…”

Section: Discussionmentioning

confidence: 99%

Ulcerative Colitis in Hematological Malignancies: Paraneoplastic Manifestation or Coincidental Bystander?

Christodoulidis

Perivoliotis

Manolakis

et al. 2020

Case Reports in Gastrointestinal Medicine

View full text Add to dashboard Cite

Evidence of coexistence of diverse hematological malignancies—lymphoma, leukemia, multiple myeloma, and myelodysplastic syndromes—and either ulcerative colitis or Crohn’s disease can be found in the literature. However, a more “systemic” effort to reach further and examine the potential of either one as paraneoplastic manifestation has not been performed. Based on these, three cases of ulcerative colitis manifesting before, simultaneously, and after the onset of different hematological malignancies are presented and critically evaluated.

show abstract

Section: Discussionmentioning

confidence: 99%

Ulcerative Colitis in Hematological Malignancies: Paraneoplastic Manifestation or Coincidental Bystander?

Christodoulidis

Perivoliotis

Manolakis

et al. 2020

Case Reports in Gastrointestinal Medicine

View full text Add to dashboard Cite

show abstract

“…Linkage analysis shows that the locus associated with inflammatory bowel disease is in the vicinity of the major histocompatibility complex (MHC) gene cluster 11 . Although studies indicate that HLA‐A, ‐B, ‐C, ‐DR, ‐DQ and ‐DP antigens and their gene loci in the HLA system are more or less associated with UC; so far, only the HLA‐DR antigens and their gene loci have been studied comprehensively 1,12−14 . Most studies have focused on the DR1 ‐ R4 antigens and gene loci, so only the DR1 ‐ R4 gene loci were investigated in the present study.…”

Section: Discussionmentioning

confidence: 99%

HLA‐DR genotypes in Chinese patients with ulcerative colitis

Peng

Guo

et al. 2002

Chinese Journal of Digestive Diseases

View full text Add to dashboard Cite

OBJECTIVE: To study HLA‐DR genotypes and to analyze the relationship between HLA‐DR genotypes, antineutrophil cytoplasmic antibodies (ANCA) and clinical classification of ulcerative colitis (UC) in Chinese patients. METHODS: Eighty UC patients and 123 healthy subjects were enrolled in the study. Serum ANCA was detected by using indirect immunofluorescence and HLA‐DR was genotyped by using the polymerase chain reaction with sequence‐specific primers (PCR‐SSCP). RESULTS: The positive rate of ANCA in UC patients was 55%, but 0.0% in the controls. The HLA‐DR2 and DR15 positive rates in the UC patients were 58.8 and 40%, respectively, which were significantly greater than 30.1 and 17.9% in the controls (P < 0.05). In the UC patients, the DR15‐positive rate was significantly higher, but the DR16‐positive rate was significantly lower in the ANCA‐positive group than in the ANCA‐negative group (52.3 vs 25.0%; 9.1 vs 30.6%, P < 0.05). The HLA‐DR2 and DR15‐positive rates in chronic persistent UC patients were significantly greater than those in the incipient or chronic recrudescent type of UC (84.2 vs 50.0 or 51.4%; 63.2 vs 29.2 or 35.1%, P < 0.05). CONCLUSIONS: In Chinese UC patients, the positive rates of HLA‐DR2 and ANCA were significantly higher compared with healthy controls. The increase in the DR2‐positive rate was associated with the increase in the DR15‐positive rate in ANCA‐positive UC patients, and was associated with the increase in the DR16 gene positive rate in ANCA‐negative UC patients. In general, HLA‐DR genotypes are related to the clinical classification of ulcerative colitis.

show abstract

Genetics of inflammatory bowel disease

Duerr

1996

Inflamm Bowel Dis

View full text Add to dashboard Cite

: Genetic influence in the susceptibility to inflammatory bowel disease (IBD) is suggested by racial, ethnic, and familial aggregation of disease. Increased concordance for IBD in monozygotic compared with dizygotic twins suggests that genetic rather than environmental factors are primarily responsible for the familial aggregation. A dramatically increased risk for IBD in siblings compared with spouses of affected individuals and many instances of temporal and geographic separation of disease onset in affected relatives also suggest that the familial aggregation of IBD is primarily due to genetic factors. The complex genetics of IBD involves incomplete penetrance and probably involves oligogenic inheritance and genetic heterogeneity. Identification of subclinical markers and markers of genetic heterogeneity in IBD to address the likely problems of incomplete penetrance and genetic heterogeneity would greatly simplify the task of finding IBD susceptibility loci in well-designed genetic marker association and linkage studies. Potential subclinical markers and markers of genetic heterogeneity in IBD are reviewed, as are candidate-gene studies. In addition to candidate-gene studies, future studies should include whole genome screening by using polymorphic genetic markers throughout the genome systematically to map IBD-susceptibility loci. Currently available molecular biologic technology with highly informative polymorphic genetic markers should permit successful identification of IBD-susceptibility genes.

show abstract

Histocompatibility Antigens (HLA-A, B) and Ulcerative Colitis in a Greek Population

Cited by 6 publications

References 6 publications

Ulcerative Colitis in Hematological Malignancies: Paraneoplastic Manifestation or Coincidental Bystander?

Ulcerative Colitis in Hematological Malignancies: Paraneoplastic Manifestation or Coincidental Bystander?

HLA‐DR genotypes in Chinese patients with ulcerative colitis

Genetics of inflammatory bowel disease

Contact Info

Product

Resources

About